AI Tool Comparison
Comparing as AI Medical Imaging & DiagnosticsPathAI vs Viz.ai
Verdict by Category
Feature & Spec Matrix
Detailed Comparison24 Criteria
Complete side-by-side breakdown of specifications, capabilities, and feature parity
Swipe horizontally to compare features
Feature / Spec
Pricing Model
EnterpriseAI pathology solutions for biopharma — Custom enterprise partnership agreements only
EnterpriseFDA-cleared AI clinical care coordination for neurovascular and cardiology — Institutional hospital and health system annual contracts
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No free plan — enterprise and biopharma contracts only; acquired by Roche in May 2026
No free plan or trial — enterprise hospital contracts via sales team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Hospital pathology labs and biopharma companies needing AI-powered digital pathology for oncology diagnostics, companion diagnostic development, and clinical trial tissue analysis
Stroke centers, cardiac centers, and health systems needing AI-powered real-time detection and automated care team coordination for acute time-sensitive conditions
Enterprise & Scalability
Difference
HIPAA compliant, CAP/CLIA certified lab services, FDA 510k cleared algorithms, SOC 2 Type II, full enterprise LIS/PACS integration, dedicated implementation and scientific support, biopharma research service contracts, and 450+ pathologist annotation network
FDA cleared (12+ algorithms), CE marked, HIPAA compliant, HITRUST certified, SOC 2 Type II, CMS New Technology Add-on Payment (NTAP) recognized, HL7/FHIR integration, enterprise SLAs, multi-site deployment, and dedicated clinical implementation support
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
AISight — cloud-native digital pathology image management, analysis, and collaboration platform
Supported
Supported
20+ FDA-cleared and research-grade AI algorithms for oncology and liver disease
Supported
Supported
32.5M+ expert pathologist annotations — one of the largest training datasets in pathology AI
Difference
PathAI Advantage
Not listed
AIM-HER2 Breast Cancer algorithm for automated HER2 scoring with aMIL heatmaps
Difference
PathAI Advantage
Not listed
PathExplore panel of human interpretable features (HIFs) for tumor microenvironment research
Difference
PathAI Advantage
Not listed
Companion diagnostics development in partnership with major pharma companies
Difference
PathAI Advantage
Not listed
CLIA-certified lab services for biopharma clinical trial tissue analysis
Difference
PathAI Advantage
Not listed
Whole slide image (WSI) management with scanner-neutral compatibility
Difference
PathAI Advantage
Not listed
Acquired by Roche in May 2026 — now backed by global diagnostic infrastructure
Supported
Supported
Partnerships with Moffitt Cancer Center, University Hospital Zurich, Bristol-Myers Squibb, and Merck
Difference
PathAI Advantage
Not listed
Real-time CT scan analysis detecting LVO strokes in under 6 minutes
Difference
Not listed
Viz.ai Advantage
Automated mobile alerts to entire care team — neurologist, ED, interventionalist — simultaneously
Difference
Not listed
Viz.ai Advantage
44% reduction in door-in-door-out (DIDO) time for LVO stroke patients
Difference
Not listed
Viz.ai Advantage
Medicare New Technology Add-on Payment (NTAP) recognized — CMS reimbursement pathway
Difference
Not listed
Viz.ai Advantage
Deployed across 1,000+ hospitals in the U.S. and Europe
Difference
Not listed
Viz.ai Advantage
Aortic disease module covering AAA, aortic dissection, and pulmonary embolism workflows
Difference
Not listed
Viz.ai Advantage
Integrated care coordination — patient referrals, pre-scan sharing, and transfer workflows
Difference
Not listed
Viz.ai Advantage
PathAI Pros & Cons
Pros
- Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
- 32.5M+ expert annotations — one of the world's largest pathology AI training datasets
- 20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
- AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
- CLIA-certified lab services for biopharma clinical trial support
- Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
- First AI pathology company recognized as a leader in CB Insights Digital Pathology market map
Cons
- Acquired by Roche in May 2026 — future product roadmap and independent operations may change
- Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
- No self-serve pricing or trial — all engagements are through enterprise procurement
- Requires digital pathology infrastructure (scanners, storage, LIS integration)
- Integration complexity for labs not yet on digital pathology workflows
Viz.ai Pros & Cons
Pros
- 12 FDA-cleared algorithms — broadest acute-condition AI portfolio in its class
- Medicare NTAP reimbursement pathway — unique among AI imaging platforms
- 44% reduction in DIDO times for stroke patients — peer-reviewed clinical evidence (ISC 2026)
- 1,000+ hospital deployments across U.S. and Europe
- Backed by Google Ventures, Kleiner Perkins, and Tiger Global — $289M raised
- Simultaneous mobile alerts to full care team — no phone-tag delays
- Expands from neurology to cardiology and pulmonology in one unified platform
Cons
- Enterprise-only pricing — no self-serve or small clinic access
- No published pricing — all contracts are custom
- Primarily focused on acute/time-sensitive conditions — not general radiology reads
- Requires integration with existing hospital imaging infrastructure
- Implementation and onboarding take time for large multi-site systems
Head-to-Head Battle Cards
Popular Comparisons
Direct feature matrices, pricing breakdowns, and real-world benchmark duels

AI Healthcare ToolsCompare

AI Healthcare ToolsCompare

AI Healthcare ToolsCompare

AI Healthcare ToolsCompare

